Simeprevir (GALEXOS) is also now covered on the Quebec formulary, according to CATIE, the Canadian AIDS Treatment Information Exchange.
However, it is only available to those who have already failed
conventional treatment with interferon and ribavirin. It is available
only to genotype 1 patients who do not have the Q80K mutation and not
co-infected with HIV.
MUST MEET ALL THESE QUALIFICATIONS TO GET REIMBURSED FOR SIMEPREVIR:
– to be used in association with ribavirin and pegylated interferon alfa– for treatment of persons suffering from chronic hepatitis C
– genotype 1 only
– without a Q80K mutation
– not HIV-1 infected, and
– have already experienced a therapeutic failure with a combination of ribavirin / pegylated interferon alfa;
Authorization for simeprevir is granted for a period of 12
weeks. The total duration of treatment, including the concomitant and
subsequent taking of the combination of ribavirin / pegylated interferon
alfa, will be 48 weeks if the viral load (HCV-RNA) is undetectable on treatment week 24.
Source: HepCBCShare This Page